Basiliximab Simulect IV 20mg Injection is a medication used to prevent organ rejection in kidney transplant recipients. It contains 20mg of basiliximab, a monoclonal antibody that works by blocking interleukin-2 (IL-2) receptors on T-cells, which are crucial for the immune response. By inhibiting IL-2, the drug helps suppress the immune system, reducing the risk of the body rejecting the transplanted kidney. The Basiliximab Simulect IV 20mg Injection is typically given intravenously in two doses: one before the transplant and another within 4 days after the procedure. It is often used alongside other immunosuppressive medications to improve transplant success.
